Illumina, Inc. (NASDAQ:ILMN) – Equities researchers at William Blair cut their Q3 2018 earnings estimates for Illumina in a report released on Monday. William Blair analyst A. Murphy now expects that the life sciences company will post earnings per share of $1.20 for the quarter, down from their previous forecast of $1.22. William Blair has a “Market Perform” rating on the stock. William Blair also issued estimates for Illumina’s Q4 2018 earnings at $1.25 EPS, FY2018 earnings at $4.55 EPS, FY2019 earnings at $5.14 EPS and FY2020 earnings at $5.87 EPS.
A number of other equities research analysts have also recently commented on the stock. Citigroup raised shares of Illumina from a “neutral” rating to a “buy” rating and increased their price objective for the company from $260.00 to $275.00 in a research note on Monday, February 5th. BidaskClub cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, February 3rd. Barclays increased their price objective on shares of Illumina from $200.00 to $215.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 31st. Morgan Stanley increased their price objective on shares of Illumina from $145.00 to $157.00 and gave the company an “underweight” rating in a research note on Wednesday, January 31st. Finally, Leerink Swann increased their price objective on shares of Illumina from $250.00 to $276.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $241.39.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.22. The business had revenue of $778.00 million during the quarter, compared to the consensus estimate of $752.04 million. Illumina had a net margin of 26.56% and a return on equity of 21.71%. The business’s revenue was up 25.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.85 EPS.
In related news, Director Robert S. Epstein sold 1,250 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $226.55, for a total value of $283,187.50. Following the sale, the director now directly owns 9,088 shares of the company’s stock, valued at $2,058,886.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director A Blaine Bowman sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $230.82, for a total transaction of $692,460.00. Following the completion of the sale, the director now directly owns 19,868 shares in the company, valued at $4,585,931.76. The disclosure for this sale can be found here. Insiders have sold a total of 114,440 shares of company stock worth $25,318,904 over the last ninety days. 0.89% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Financial Gravity Companies Inc. acquired a new stake in shares of Illumina in the fourth quarter worth approximately $106,000. Advisory Services Network LLC boosted its position in shares of Illumina by 13.0% in the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after acquiring an additional 89 shares during the last quarter. Dupont Capital Management Corp acquired a new stake in shares of Illumina in the third quarter worth approximately $153,000. SeaCrest Wealth Management LLC acquired a new stake in shares of Illumina in the fourth quarter worth approximately $154,000. Finally, Captrust Financial Advisors acquired a new stake in shares of Illumina in the fourth quarter worth approximately $165,000. 92.04% of the stock is currently owned by institutional investors and hedge funds.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.